Jaideep Dudani, Ouro Medicines CEO
With $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years.
The cell-depleting medicines, known simply as TCEs, are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
